Eptifibatide. Platelet antiaggregatory, glycoprotein IIb/IIIa antagonist, fibrinogen receptor antagonist

Drugs of the Future

Volumn 23, Issue 6, 1998, Pages 585-590

  Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 AMINOBENZENESULFONYL) 3 BUTYLUREA; ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CREATINE KINASE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0031849692     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.06.461706     Document Type: Review

References (41)

1. Scarborough, R.M., Naughton, M.A., Teng, W., Rose, J.W., Phillips, D.R., Nannizzi, L., Arfsten, A., Campbell, A.M., Charo, I.F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993, 268: 1066-73.
2. White, H.D. Unmet therapeutic needs in the management of acute ischemia. Amer J Cardiol 1997, 80: 2B-10B.
3. Phillips, D.R., Charo, I.F., Scarborough, R.M. GPIIb-IIIa: The responsive integrin. Cell 1991, 65: 359-62.
4. Davies, M.J. Pathology of arterial thrombosis. Brit Med Bull 1994, 50: 789-802.
5. Falk, E. Role of thrombosis in atherosclerosis and its complications. Amer J Cardiol 1995, 75: 3B-11B.
6. Lefkovits, J., Plow, E.F., Topol, E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New Engl J Med 1995, 332: 1553-9.
7. Coller, B.S. Platelets and thrombolytic therapy. New Engl J Med 1990, 322: 33-42.
8. Chesebro, J.H., Fuster, V. Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: The basis of their use, data from animal studies, clinical trial data, and current recommendations. Cardiology 1986, 73: 292-305.
9. Harker, L.A. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Amer J Cardiol 1987, 60: 20B-8B.
10. Bittl, J.A. Advances in coronary angioplasty. New Engl J Med 1996, 335: 1290-302.
11. Robinson, C. Abciximab. Drugs Fut 1995, 20: 457-63.
12. Genatta, T.B., Mauro, V.F. Abciximab: A new antiaggregant used in angioplasty. Ann Pharmacol 1996, 30: 251-7.
13. Pytela, R., Pierschbacher, M.D., Ginsberg, M.H., Plow, E.F., Ruoslahti, E. Platelet membrane glycoprotein IIb/IIIa: Member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986, 231: 1559-62.
14. Kouns, W.C., Roux, S., Steiner, B. Human platelet GPIIb-IIIa receptor blockade as a therapeutic strategy. Curr Opin Invest Drugs 1993, 2: 475-94.
15. Cook, N.S., Kottirsch, G., Zerwes, H.-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Fut 1994, 19: 135-59.
16. Zablocki, J.A., Nicholson, N.S., Feigen, L.P. Fibrinogen receptor antagonists. Exp Opin Invest Drugs 1994, 3: 437-48.
17. Topol, E.J. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998, 97: 211-8.
18. Raddatz, P., Gante, J. Recent developments in glycoprotein IIb/IIIa antagonists. Exp Opin Ther Patents 1995, 5: 1163-83.
19. Scarborough, R.M., Hsu, M.A., Teng, W., Rose, J.W., Philips, D.R., Campbell, A.M., Nannizzi, L., Charo, I.F. C68-22, a novel glycoprotein (GP) IIb-IIIa specific platelet aggregation inhibitor designed from the structure of barbourin. Arterioscler Thromb 1991, 11: 1591a.
20. 2+ on GPIIb-IIIa interactions with Integrilin: Enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reduction in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997, 96: 1488-94.
21. 3 integrins. J Biol Chem 1996, 271: 10365-71.
22. Strony, J., Adelman, B., Phillips, D.R., Scarborough, R.M., Charo, I.F. Inhibition of platelet thrombus formation in an in vivo model of high shear stress by a glycoprotein IIb-IIIa specific peptide antagonist. Circulation 1991, 84(4, Suppl. 2): Abst 0985.
23. Song, A., Scarborough, R.M., Phillips, D.R., Adelman, B., Strony, J. Integrelin enhances fibrinolysis and prevents acute arterial reocclusion following thrombolysis in a canine anodal current model with high grade stenosis. Circulation 1992, 86(4, Suppl. 1): Abst 1634.
24. Nicolini, F.A., Philmo, L., Rios, G., Kottke-Marchant, K., Topol, E. J. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994, 89: 1802-9.
25. Uthoff, K., Zehr, K.J., Geerling, R., Herskowitz, A., Cameron, D.E., Reitz, B.A. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. Circulation 1994, 90: II-269-74.
26. Hanson, S.R., Kotze, H.F., Harker, L.A., Scarborough, R.M., Charo, I.F., Phillips, D.R. Potent antithrombotic effects of novel peptide antagonists of platelet glycoprotein (GP) IIb-IIIa. Thromb Haemost 1991, 65: 813.
27. Hanson, S.R., Markou, C., Lindahl, A.K. et al. Inhibition of in vivo thrombus formation in an arterial stenosis model. Thromb Haemost 1993, 69: 540.
28. Van Wart, S., Kosoglou, T., Tcheng, J.E., Lorenz, T., Alton, K., Belanger, B., Radwanski, E. Eptifibatide pharmacokientics in patients undergoing coronary angioplasty. Clin Pharmacol Ther 1998, 63: Abst PIII-103.
29. 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998, 20: 307-23.
30. Charo, I.F., Scarborough, R.M., du Mee, C.P., Wolf, D., Phillips, D.R., Swift, R.L. Pharmacodynamics of the GPIIb-IIIa antagonist Integrelin: Phase I clinical studies in normal healthy volunteers. Circulation 1992, 86(4, Suppl. 1): Abst 1034.
31. Phillips, D.R., Scarborough, R.M. Clinical pharmacology of eptifibatide. Amer J Cardiol 1997, 80: 11B-20B.
32. Tcheng, J.E., Harrington, R.A., Kottke-Marchant, K. et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet intregrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary angioplasty. Circulation 1995, 91: 2151-7.
33. Harrington, R.A., Kleiman, N.S., Kottke-Marchant, K. et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Amer J Cardiol 1995, 76: 1222-7.
34. Kamat, S.G., Turner, N.A., Konstantopoulos, K., Hellums, J.D., McIntire, L.V., Kleiman, N.S., Moake, J.L. Effects of Integrelin on platelet function in flow models of arterial thrombosis. J Cardiovasc Pharmacol 1997, 29: 156-63.
35. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997, 349: 1422-8.
36. Tcheng, J.E. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: A review of the IMPACT II trial. Amer J Cardiol 1997, 80: 21B-8B.
37. Kleiman, N.S. Primary and secondary safety endpoints from IMPACT II. Amer J Cardiol 1997, 80: 29B-33B.
38. Schulman, S.P., Goldschmidt-Clermont, P.J., Topol, E.J. et al. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. Circulation 1996, 94: 2083-9.
39. Harrington et al. A randomized comparison of the platelet glycoprotein IIb/IIIa peptide inhibitor eptifibatide with placebo in patients without persistent ST-segment elevation acute coronary syndromes. New Engl J Med 1998, in press.
40. Ohman, E.M., Kleiman, N.S., Gacioch, G. et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. Circulation 1997, 95: 846-54.
41. ™ available week of June 1st. Cor Therapeutics, Inc. Company Communication May 27, 1998.